首页> 外文期刊>International Journal of Cancer =: Journal International du Cancer >A prognostic classifier consisting of 17 circulating cytokines is a novel predictor of overaE survival for metastatic colorectal cancer patients
【24h】

A prognostic classifier consisting of 17 circulating cytokines is a novel predictor of overaE survival for metastatic colorectal cancer patients

机译:由17种循环细胞因子组成的预后分类器是转移性结直肠癌患者overaE存活的新预测指标

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

We aimed to determine the prognostic values of 39 circulating cytokines in Chinese patients with metastatic colorectal cancer (CRC) and to develop a novel cytokine-based prognostic classifier (CBPC) for prognostic prediction. A total of 176 patients were divided into two cohorts based on the date of first-line chemotherapy. The first 99 cases were assigned to the training cohort, and the remaining 77 cases were assigned to the validation cohort. Thirty-nine cytokines were simultaneously analyzed in the patient serum samples using multiplex bead-based Luminex technology. We used support vector machine-based methods and Cox proportional hazards models to develop a CBPC from the training cohort, which we then validated using the second patient cohort. Univariate analysis showed that FGF-2, TGFas Flt-3L, GM-CSF, !NFa2, GROS IL-10, MCP-3, AADC, s!L-2Ra, IL.-2, IL-7, IL-8, MCP-1, MIP-ip, TNFa and VEGF were significant risk factors affecting the overall survival (OS) of both the training cohort and the validation cohort. We developed a CBPC to predict the OS of metastatic CRC patients using these 17 cytokines (sensitivity, 0.835; specificity, 0.800). in the validation cohort, the CBPC was found to have significant power in predicting the OS of metastatic CRC patients. Our study showed that there were significant associations between cytokine expression and prognosis of the patients with metastatic CRC. The CBPC that we developed includes multiple circulating cytokines and may serve as a novel screening tool for identifying metastatic CRC patients with a high risk of short OS. These high-risk individuals may also be suitable for cytokine-targeted therapies.
机译:我们旨在确定39种循环细胞因子在中国转移性结直肠癌(CRC)患者中的预后价值,并开发一种基于细胞因子的新型预后分类器(CBPC)进行预后预测。根据一线化疗的日期,总共176例患者被分为两个队列。前99例被分配到训练队列,其余77例被分配到验证队列。使用基于多重磁珠的Luminex技术同时分析了患者血清样品中的39种细胞因子。我们使用基于支持向量机的方法和Cox比例风险模型从训练队列中开发出CBPC,然后我们使用第二个患者队列进行了验证。单变量分析显示FGF-2,TGFas Flt-3L,GM-CSF,!NFa2,GROS IL-10,MCP-3,AADC,s!L-2Ra,IL.-2,IL-7,IL-8, MCP-1,MIP-ip,TNFa和VEGF是影响训练队列和验证队列总体生存(OS)的重要危险因素。我们开发了一种CBPC来预测使用这17种细胞因子引起的转移性CRC患者的OS(敏感性0.835;特异性0.800)。在验证队列中,发现CBPC在预测转移性CRC患者的OS中具有重要作用。我们的研究表明,细胞因子的表达与转移性CRC患者的预后之间存在显着关联。我们开发的CBPC包含多种循环细胞因子,可以作为一种新颖的筛查工具,用于识别具有短OS高风险的转移性CRC患者。这些高风险个体也可能适用于针对细胞因子的疗法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号